Work

Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB)

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-2987

Authors: Daniel S. Lieber, Mark R. Kennedy, Douglas B. Johnson, Jonathan E. Rosenberg, Marcin Kowanetz, Joel R. Greenbowe, Garrett M. Frampton, Caitlin F. Connelly, Alexa B. Schrock, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Vincent A. Miller, David A. Fabrizio

Institutions: Foundation Medicine (United States), Vanderbilt University, Memorial Sloan Kettering Cancer Center, Genentech

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2739585247

Cites:

Cited by: 3

Related to: 10